nach oben

Journal of Nephrology

Erschienen in:

01.12.2016 | Review

Microalbuminuria in primary hypertension: a guide to optimal patient management?

verfasst von: Francesca Viazzi, Francesca Cappadona, Roberto Pontremoli

Erschienen in: Journal of Nephrology | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Abstract

Accurate assessment of the global risk profile is considered a prerequisite for the optimal management of hypertensive patients. In particular, the evaluation of subclinical organ damage, namely left ventricular hypertrophy, peripheral atherosclerosis and renal function, plays a key role in optimizing therapeutic targets and strategy in individual patients. Urine albumin excretion is a low-cost, easy-to-use test and a powerful predictor of cardiovascular diseases. The search for albuminuria has, therefore, become routine in the evaluation of hypertensive patients. Moreover, albuminuria has been shown to be associated with early signs of extra-renal organ damage such as left ventricular hypertrophy, and carotid atherosclerosis. Under effective antihypertensive treatment, changes in subclinical organ damage over time, especially regression of left ventricular hypertrophy, are paralleled by modification of risk status and may serve as intermediate endpoints for treatment. More recently, changes in albuminuria have also been proposed to reflect changes in the risk of cardiovascular events. If this is confirmed by large well-designed studies, microalbuminuria may not simply be regarded as a risk predictor but become itself an independent target for treatment.

Viazzi F, Leoncini G, Parodi D, Ratto E, Vettoretti S, Vaccaro V, Parodi A, Falqui V, Tomolillo C, Deferrari G, Pontremoli R (2005) Impact of target organ damage assessment in the evaluation of global risk in patients with essential hypertension. J Am Soc Nephrol 16(Suppl 1):S89–S91CrossRefPubMed

Devereux RB, Alderman MH (1993) Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 88:1444–1455CrossRefPubMed

Leoncini G, Ratto E, Viazzi F, Conti N, Falqui V, Parodi A et al (2008) Global risk stratification in primary hypertension: the role of the kidney. J Hypertens 26:427–432CrossRefPubMed

Leoncini G, Sacchi G, Viazzi F, Ravera M, Parodi D, Ratto E, Vettoretti S, Tomolillo C, Deferrari G, Pontremoli R (2002) Microalbuminuria identifies overall cardiovascular risk in essential hypertension: an artificial neural network-based approach. J Hypertens 20:1315–1321CrossRefPubMed

Pedrinelli R, Dell’Omo G, di Bello V, Pontremoli R, Mariani M (2002) Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 16:79–89CrossRefPubMed

Pontremoli R (1996) Microalbuminuria in essential hypertension–its relation to cardiovascular risk factors. Nephrol Dial Transpl 11:2113–2115CrossRef

Viazzi F, Leoncini G, Ratto E, Vaccaro V, Tomolillo C, Falqui V, Parodi A, Conti N, Deferrari G, Pontremoli R (2006) Microalbuminuria, blood pressure load, and systemic vascular permeability in primary hypertension. Am J Hypertens 19:1183–1189CrossRefPubMed

Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, Kleefstra N, Naimark D, Roderick P, Tonelli M, Wetzels JF, Astor BC, Gansevoort RT, Levin A, Wen CP, Coresh J, Chronic Kidney Disease Prognosis Consortium (2012) Age and association of kidney measures with mortality and end-stage renal disease. JAMA 308:2349–2360CrossRefPubMedPubMedCentral

Savarese G, Dei Cas A, Rosano G, D’Amore C, Musella F, Mosca S et al (2014) Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials. Int J Cardiol 172:403–410CrossRefPubMed

10.

Devereux RB, de Simone G, Roman MJ (1997) Relations of left ventricular geometry and function to prognosis in hypertension. Adv Exp Med Biol 432:1–12CrossRefPubMed

11.

Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, Cífková R, Cosentino F, De Carlo M, Gallino A, Landmesser U, Laurent S, Lekakis J, Mikhailidis DP, Naka KK, Protogerou AD, Rizzoni D, Schmidt-Trucksäss A, Van Bortel L, Weber T, Yamashina A, Zimlichman R, Boutouyrie P, Cockcroft J, O’Rourke M, Park JB, Schillaci G, Sillesen H, Townsend RR (2015) The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. Atherosclerosis 241:507–532CrossRefPubMed

12.

Viazzi F, Parodi D, Leoncini G, Vettoretti S, Ratto E, Vaccaro V, Ravera M, Tomolillo C, Bezante GP, Del Sette M, Deferrari G, Pontremoli R (2004) Optimizing global risk evaluation in primary hypertension: the role of microalbuminuria and cardiovascular ultrasonography. J Hypertens 22:907–913CrossRefPubMed

13.

Mancia G, Fagard R, Narkiewicz K, Redo´n J, Zanchetti A, Bo¨hm M, Task Force Members et al (2013) ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013(31):1281–1357CrossRef

14.

Viazzi F, Leoncini G, Pontremoli R (2013) Global cardiovascular risk assessment in the management of primary hypertension: the role of the kidney. Int J Hypertens 2013:542646CrossRefPubMedPubMedCentral

15.

Pontremoli R, Leoncini G, Viazzi F, Ratto E, Vaccaro V, Falqui V, Parodi A, Conti N, Tomolillo C, Deferrari G (2006) Evaluation of subclinical organ damage for risk assessment and treatment in the hypertensive patient: role of microalbuminuria. J Am Soc Nephrol 17:S112–S114CrossRefPubMed

16.

Devereux RB, Agabiti-Rosei E, Dahlöf B, Gosse P, Hahn RT, Okin PM, Roman MJ, Pierdomenico SD, Lapenna D, Cuccurullo F (2008) Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens 21:464–470CrossRef

17.

Devereux RB, Agabiti-Rosei E, Dahlöf B, Gosse P, Hahn RT, Okin PM, Roman MJ (1996) Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials. J Hypertens Suppl 14:S95–S101CrossRefPubMed

18.

Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E (1995) Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 13:1091–1095CrossRefPubMed

19.

Leoncini G, Viazzi F, Pontremoli R (2010) Overall health assessment: a renal perspective. Lancet 375:2053–2054CrossRefPubMed

20.

Weir MR (2007) Effects of renin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 29:1803–1824CrossRefPubMed

21.

Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE (2003) A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115:41–46CrossRefPubMed

22.

Keen H, Chlouverakis C (1963) An immunoassay method for urinary albumin at low concentrations. Lancet 2:913–914CrossRefPubMed

23.

Mogensen CE (1971) Urinary albumin excretion in diabetes. Lancet 11(2):601–602CrossRef

24.

Parving HH, Rossing N, Jensen HA (1974) Increased metabolic turnover rate and transcapillary escape rate of albumin in essential hypertension. Circ Res 35:544–552CrossRefPubMed

25.

Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H (1982) Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 26(1):1430–1432CrossRef

26.

Viazzi F, Leoncini G, Conti N, Tomolillo C, Giachero G, Vercelli M et al (2010) Combined effect of albuminuria and estimated glomerular filtration rate on cardiovascular events and all-cause mortality in uncomplicated hypertensive patients. J Hypertens 28:848–855CrossRefPubMed

27.

Viazzi F, Leoncini G, Conti N, Tomolillo C, Giachero G, Vercelli M et al (2010) Microalbuminuria is a predictor of chronic renal insufficiency in patients without diabetes and with hypertension: the MAGIC study. Clin J Am Soc Nephrol 5:1099–1106CrossRefPubMedPubMedCentral

28.

Viazzi F, Pontremoli R (2016) Albuminuria: the kidney message on cardio-vascular health. J Hypertens 34:399–401CrossRefPubMed

29.

Pontremoli R, Leoncini G, Viazzi F, Parodi D, Vaccaro V, Falqui V, Parodi A, Vettoretti S, Ratto E, Deferrari G (2005) Role of microalbuminuria in the assessment of cardiovascular risk in essential hypertension. J Am Soc Nephrol 16(Suppl 1):S39–S41CrossRefPubMed

30.

Tylicki L, Puttinger H, Rutkowski P, Rutkowski B, Horl WH (2006) Smoking as a risk factor for renal injury in essential hypertension. Nephron Clin Pract 103:c121–c128CrossRefPubMed

31.

Pedrinelli R, Giampietro O, Carmassi F, Melillo E, Dell’Omo G, Catapano G, Matteucci E, Talarico L, Morale M, De Negri F et al (1994) Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 2(344):14–18CrossRef

32.

Alberti FG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15:539–553CrossRefPubMed

33.

Viazzi F, Pontremoli R (2014) Blood pressure, albuminuria and renal dysfunction: the ‘chicken or egg’ dilemma. Nephrol Dial Transpl 29:1453–1455CrossRef

34.

Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, Jafar T, Jassal SK, Landman GW, Muntner P, Roderick P, Sairenchi T, Schöttker B, Shankar A, Shlipak M, Tonelli M, Townend J, van Zuilen A, Yamagishi K, Yamashita K, Gansevoort R, Sarnak M, Warnock DG, Woodward M, Ärnlöv J; CKD Prognosis Consortium (2015) Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 3:514–525

35.

Liu C, Chen H, Liu C, Fu C, Zhang H, Yang H, Wang P, Wang F, Chen S, Ma Q (2014) Combined application of eGFR and albuminuria for the precise diagnosis of stage 2 and 3a CKD in the elderly. J Nephrol 27:289–297CrossRefPubMed

36.

Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlöf B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Okin PM, Omvik P, Oparil S, Wedel H, Snapinn SM, Aurup P (2003) Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 139:901–906CrossRefPubMed

37.

Leoncini G, Viazzi F, Conti N, Baratto E, Tomolillo C, Bezante GP, Deferrari G, Pontremoli R (2009) Renal and cardiac abnormalities in primary hypertension. J Hypertens 27:1064–1073CrossRefPubMed

38.

Pontremoli R, Sofia A, Ravera M, Nicolella C, Viazzi F, Tirotta A, Ruello N, Tomolillo C, Castello C, Grillo G, Sacchi G, Deferrari G (1997) Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. Microalbuminuria: a Genoa Investigation on Complications. Hypertension 30:1135–1143CrossRefPubMed

39.

Viazzi F, Bonino B, Ratto E, De Cosmo S, Pontremoli R (2014) Early renal abnormalities as an indicator of cardiovascular risk in type 2 diabetes. High Blood Press Cardiovasc Prev 21:257–260CrossRefPubMed

40.

Pontremoli R, Leoncini G, Ravera M, Viazzi F, Vettoretti S, Ratto E, Parodi D, Tomolillo C, Deferrari G (2002) Microalbuminuria, cardiovascular, and renal risk in primary hypertension. J Am Soc Nephrol 13(3):S169–S172CrossRefPubMed

41.

Pontremoli R, Ravera M, Bezante GP, Viazzi F, Nicolella C, Berruti V, Leoncini G, Del Sette M, Brunelli C, Tomolillo C, Deferrari G (1999) Left ventricular geometry and function in patients with essential hypertension and microalbuminuria. J Hypertens 17:993–1000CrossRefPubMed

42.

Pontremoli R, Nicolella C, Ravera M, Viazzi F, Berruti V, Ruello N, Tomolillo C, Bezante GP, Del Sette M, Martinoli C, Sacchi G, Deferrari G (1998) Microalbuminuria is an early marker of target organ damage in essential hypertension. Am J Hypertens 11:430–438CrossRefPubMed

43.

Ravera M, Ratto E, Vettoretti S, Viazzi F, Leoncini G, Parodi D, Tomolillo C, Del Sette M, Maviglio N, Deferrari G, Pontremoli R (2002) Microalbuminuria and subclinical cerebrovascular damage in essential hypertension. J Nephrol 15:519–524PubMed

44.

Pontremoli R, Viazzi F, Martinoli C, Ravera M, Nicolella C, Berruti V, Ruello N, Tomolillo C, Bezante GP, Del Sette M, Derchi LE, Deferrari G (1999) Increased renal resistive index in patients with essential hypertension: a marker of organ damage. Nephrol Dial Transpl 14:360–365CrossRef

45.

Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT (2010) Association of estimated glomerular filtration rate and albuminuria with all- cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 375:2073–2081CrossRefPubMedPubMedCentral

46.

Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE et al (2006) Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study. Diabet Care 29:595–600CrossRef

47.

Tanaka F, Komi R, Makita S, Onoda T, Tanno K, Ohsawa M et al (2016) Low-grade albuminuria and incidence of cardiovascular disease and all-cause mortality in nondiabetic and normotensive individuals. J Hypertens 34:506–512CrossRefPubMed

48.

Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE, Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group (2002) Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 1(106):1777–1782CrossRef

49.

Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE et al (2005) Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention For Endpoint Reduction in Hypertension study. Hypertension 45:198–202CrossRefPubMed

50.

Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V, Chiang YT, Weber MA, ACCOMPLISH Trial investigators (2010) Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 375:1173–1181CrossRefPubMed

51.

Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, ONTARGET Investigators et al (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358:1547–1555CrossRefPubMed

52.

Schmieder RE, Mann JF, Schumacher H, Gao P, Mancia G, Weber MA et al (2011) ONTARGET Investigators. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 22:1353–1364CrossRefPubMedPubMedCentral

53.

Viazzi F, Muiesan ML, Schillaci G, Salvetti M, Pucci G, Bonino B, Signori A, Pontremoli R. Changes in albuminuria and cardiovascular risk under antihypertensive treatment: a systematic review and meta-regression analysis J Hypertens (in press)

54.

Leoncini G, Viazzi F, Conti N, Baratto E, Tomolillo C, Bezante GP, Deferrari G, Pontremoli R (2009) Renal and cardiac abnormalities in primary hypertension. J Hypertens 27:1064–1073CrossRefPubMed

55.

Ratto E, Viazzi F, Bonino B, Gonnella A, Garneri D, Parodi EL, Bezante GP, Derchi LE, Leoncini G, Pontremoli R (2015) Left ventricular dilatation and subclinical renal damage in primary hypertension. J Hypertens 33:605–611CrossRefPubMed

Titel: Microalbuminuria in primary hypertension: a guide to optimal patient management?
verfasst von: Francesca Viazzi
Francesca Cappadona
Roberto Pontremoli
Publikationsdatum: 01.12.2016
Verlag: Springer International Publishing
Erschienen in: Journal of Nephrology / Ausgabe 6/2016
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-016-0335-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Microalbuminuria in primary hypertension: a guide to optimal patient management?

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2016

Podocyturia is significantly elevated in untreated vs treated Fabry adult patients

Metformin modulates apoptosis and cell signaling of human podocytes under high glucose conditions

Urinary retinol-binding protein as a risk factor of poor prognosis in acute-on-chronic renal injury

Dialysis requirement, long-term major adverse cardiovascular events (MACE) and all-cause mortality in hospital acquired acute kidney injury (AKI): a propensity-matched cohort study

Respiratory muscle impairment in dialysis patients: can minimal dose of exercise limit the damage? A Preliminary study in a sample of patients enrolled in the EXCITE trial

Metformin associated lactic acidosis (MALA): clinical profiling and management

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Costims – das nächste heiße Ding in der Krebstherapie?

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

Update Innere Medizin